Plasma Hsp90α Biomarker for Cancer Metastasis Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor biomarkers for cancer detection lack sensitivity and specificity, making early detection and differentiation between benign and malignant tumors challenging, and there is a need for new technologies to improve diagnosis and treatment monitoring.
Innovation Solution
The discovery of plasma Hsp90α as a novel tumor biomarker, which is correlated with cancer development, malignancy, and metastasis, allowing for its use in detecting cancer presence, stage, and metastasis through specific antibody binding, and potentially inhibiting cancer invasiveness and metastasis by targeting its phosphorylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional tumor biomarkers (AFP, CA-125, CA15-3) are used for cancer detection, then some diagnostic capability is provided, but sensitivity and specificity are insufficient for early detection and differentiation of benign vs. malignant tumors
Solution Approach 1:
The patent shifts from detecting conventional biomarkers (AFP, CA-125, CA15-3) to detecting plasma Hsp90α, a previously unrecognized biomarker parameter. This parameter change enables early detection of cancer before clinical symptoms appear and provides superior differentiation between benign and malignant tumors, directly resolving the sensitivity and specificity limitations of existing markers
2Productivity
If current tumor biomarkers are used for monitoring disease progression and treatment response, then some monitoring capability is provided, but the ability to detect cancer occurrence early and monitor treatment response accurately is limited
Solution Approach 1:
The patent introduces plasma Hsp90α as a new monitoring parameter that correlates with cancer development, malignancy, and metastasis. This enables accurate monitoring of treatment response and disease progression, providing superior precision compared to conventional biomarkers while maintaining monitoring efficiency
3Adaptability or versatility
If Hsp90α is targeted for inhibiting cancer metastasis, then new therapeutic capability is provided, but the mechanism for preventing cancer invasiveness and metastasis needs to be established
Solution Approach 1:
The patent identifies phosphorylation of Hsp90α as a key mechanism in cancer metastasis and targets this process for inhibition. By interfering with the phosphorylation of Hsp90α, the patent prevents cancer cells from acquiring invasive and metastatic capabilities, providing a reliable therapeutic mechanism that addresses the root cause of metastasis rather than just treating established disease
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Plasma Hsp90α levels accurately predict cancer malignancy and metastasis, enabling effective diagnosis, prognosis, and treatment monitoring, and inhibiting its phosphorylation can prevent cancer metastasis, providing a new target for anticancer therapies.
Implementation Method 1
detecting the level of a polypeptide comprising or consisting of the amino acid sequence of SEQ ID No. 1 in a plasma sample of the subject by using an agent capable of specifically binding to said polypeptide
Implementation Method 2
a method of inhibiting cancer invasiveness and metastasis, comprising the step of inhibiting the phosphorylation of Hsp90α in cancer cells
Data Source
AI summary
The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.